Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.945 SEK | -1.17% | -0.34% | -61.55% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2024 * | 82.38M 7.62M | Sales 2025 * | 196M 18.09M | Capitalization | 291M 26.89M |
---|---|---|---|---|---|
Net income 2024 * | -244M -22.56M | Net income 2025 * | -174M -16.09M | EV / Sales 2024 * | 1.85 x |
Net cash position 2024 * | 138M 12.79M | Net Debt 2025 * | 62.58M 5.79M | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
-1.95
x | P/E ratio 2025 * |
-2.86
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | -0.91% | ||
1 week | -0.34% | ||
Current month | +1.20% | ||
1 month | -48.15% | ||
3 months | -56.36% | ||
6 months | -59.11% | ||
Current year | -61.55% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 2.945 | -1.17% | 647 917 |
24-05-03 | 2.98 | +2.23% | 922,348 |
24-05-02 | 2.915 | +0.17% | 1,117,011 |
24-04-30 | 2.91 | -1.69% | 1,365,268 |
24-04-29 | 2.96 | +0.17% | 2,321,014 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.55% | 27.25M | |
+9.22% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.47% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.95% | 16.96B | |
+7.58% | 14.16B | |
+40.03% | 12.63B |
- Stock Market
- Equities
- ONCO Stock